Kardigan (KARD) closed its initial public offering of 28.75 million shares, including the full exercise of the underwriters' option to purchase an additional 3.75 million.
Gross proceeds were $460 million before underwriting discounts and offering expenses with the shares sold at $16 each, the clinical-stage cardiovascular drug developer said Monday in a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.